International Journal of Hematology

, Volume 83, Issue 3, pp 266–270 | Cite as

Prevention of Cytomegalovirus Infection by Valaciclovir after Allogeneic Bone Marrow Transplantation from an Unrelated Donor

  • Takehiko Mori
  • Yoshinobu Aisa
  • Takayuki Shimizu
  • Tomonori Nakazato
  • Rie Yamazaki
  • Yasuo Ikeda
  • Shinichiro Okamoto
Case Report


In this prospective single-center study, we evaluated the efficacy and safety of valaciclovir (VACV) in the prevention of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (BMT).The study population consisted of 12 patients who underwent allogeneic BMT from an unrelated donor. Patients received acyclovir (ACV) intravenously until they became able to take VACV orally.VACV was administered at a daily dose of 3000 mg and continued until day 100. CMV infection was monitored by CMV antigenemia assay and real-time polymerase chain reaction analysis of plasma. Thirty-five patients who did not receive any form of CMV chemoprophylaxis served as control subjects. CMV infection was detected in 4 (33.3%) of the 12 patients and in 24 (68.6%) of the 35 control subjects (P > .05). The onset of CMV infection was significantly delayed in the VACV group (median, day 43) compared with the control group (median, day 28.5; P > .01). Gastrointestinal symptoms as an adverse event due to VACV administration were observed in 2 patients. The plasma levels of ACV after VACV administration were measured in 8 patients and were similar to those in the healthy subjects. In conclusion,VACV shows normal absorption, even in the early posttransplantation period, and may prevent or delay CMV infection effectively and safely in allogeneic BMT recipients.

Key words

Cytomegalovirus Valaciclovir Allogeneic BMT 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Myers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478–488.CrossRefGoogle Scholar
  2. 2.
    Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis. 1999;12(suppl 7):S776-S792.Google Scholar
  3. 3.
    Ljungman P, Reusser P, de la Camara R, et al, for the Infectious Disease Working Party of the European Group for Blood and Marrow Transplantation. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075–1081.CrossRefGoogle Scholar
  4. 4.
    Boeckh M, Fries B, Garrett NW. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant. 2004;8(suppl 5):19–27.CrossRefGoogle Scholar
  5. 5.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–178.CrossRefGoogle Scholar
  6. 6.
    Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179–184.CrossRefGoogle Scholar
  7. 7.
    Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063–4071.Google Scholar
  8. 8.
    Schmidt GM, Horak D, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: the City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005–1011.CrossRefGoogle Scholar
  9. 9.
    Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:765–769.CrossRefGoogle Scholar
  10. 10.
    Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:777–782.CrossRefGoogle Scholar
  11. 11.
    Choi S-M, Lee D-G, Choi J-H, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic bone marrow transplantation: a single-center experience in Korea. Int J Hematol. 2005;81:69–74.CrossRefGoogle Scholar
  12. 12.
    Mori T, Aisa Y, Nakazato T, Okamoto S. Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hemato-poietic stem cell transplantation. Int J Hematol. 2005;81:439–440.CrossRefGoogle Scholar
  13. 13.
    Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell trans-plantation. Bone Marrow Transplant. 2004;33:431–434.CrossRefGoogle Scholar
  14. 14.
    Talarico CT, Burnette TC, Miller WH, et al. Acyclovir is phospho-rylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother. 1999;43:1941–1946.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996;52:754–772.CrossRefGoogle Scholar
  16. 16.
    Tyms AS, Scamans EM, Naim HM. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections. J Antimicrob Chemother. 1981;8:65–72.CrossRefGoogle Scholar
  17. 17.
    Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis. 1987;6:255–261.CrossRefGoogle Scholar
  18. 18.
    Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70–75.CrossRefGoogle Scholar
  19. 19.
    Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343:749–753.CrossRefGoogle Scholar
  20. 20.
    Ljungman P, de la Camara R, Milpied N, et al, and the Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99:3050–3056.CrossRefGoogle Scholar
  21. 21.
    Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC, and the Valacyclovir Cytomegalovirus Study Group. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36:749–758.CrossRefGoogle Scholar
  22. 22.
    Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828.PubMedGoogle Scholar
  23. 23.
    Kurihara T, Hayashi J, Matusoka T, et al. HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method. Biomed Res. 1995;16:125–129.CrossRefGoogle Scholar
  24. 24.
    Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595–605.CrossRefGoogle Scholar
  25. 25.
    Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39:2759–2764.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Vusirikala M, Wolff SN, Stein RS, et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. 2001;28:265–270.CrossRefGoogle Scholar
  27. 27.
    Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection: AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1998;177:48–56.CrossRefGoogle Scholar
  28. 28.
    Lowance D, Neumayer H-H, Legendre CM, et al, for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462–1470.CrossRefGoogle Scholar
  29. 29.
    Ho VT, Cutler C, Carter S, et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thromobotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–575.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Takehiko Mori
    • 1
  • Yoshinobu Aisa
    • 1
  • Takayuki Shimizu
    • 1
  • Tomonori Nakazato
    • 1
  • Rie Yamazaki
    • 1
  • Yasuo Ikeda
    • 1
  • Shinichiro Okamoto
    • 1
  1. 1.Division of Hematology, Department of MedicineKeio University School of MedicineTokyoJapan

Personalised recommendations